Drug Trial Radar · NCT04679870
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
21
Planned (sponsor's estimate)
Start
Jun 9, 2021
Primary completion
Dec 31, 2023
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Galecto Biotech ABIndustry
- Sponsor type
- Industry
- Collaborators
- OPIS s.r.l
- First posted
- Dec 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open label, phase IIa trial in subjects with Myelofibrosis
Conditions
- Myelofibrosis
Interventions
GB2064Drug
GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of GB2064: AETime frame: 9 Months
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
MD Andersson Cancer Hospital
Houston, Texas
Woden Dermatology
Canberra, Australia
Heinrich-Heine-University Dusseldorf
Düsseldorf, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany
Universität Leipzig
Leipzig, Germany
Klinikum rechts der Isar der Technischen Universitaet Munchen
München, Germany
University of Bologna Sant Orsola Malpighi
Bologna, Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga di Orbassano
Orbassano, Italy
Azienda Socio-Sanitaria Territoriale dei Sette Laghi
Varese, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.